The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense (DoD) Melanoma Research Program (MRP)to support innovative, high-impact melanoma research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 MRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

The FY19 MRP Focus Areas are listed below:

• Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
• Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
• Therapeutic Prevention
• Minimal Residual Disease
• Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)

The MRP challenges the research community to redefine the concept of prevention and has issued a FY19 MRP Challenge Statement that should be considered when responding to the FY19 MRP Focus Areas and funding opportunities.

https://cdmrp.army.mil/funding/mrp

Idea Award – Preproposal due July 26, 2019

Independent investigators with a faculty-level appointment (or equivalent)

·      Preproposal is required; application submission is by invitation only.

·      Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research.

·      Emphasis on Innovation and Impact

·      Preliminary data are not required.

·      Clinical trials are not allowed.

·      The maximum allowable funding for the entire period of performance is $300,000 for direct costs

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

·      Maximum period of performance is 3 years

Team Science Award – Preproposal due July 26, 2019

At least two and up to three investigators must partner in one overarching multidisciplinary research study.

Initiating Principal Investigator (PI):

Independent investigators at or above the level of Associate Professor (or equivalent).

Partnering PI: Independent investigators at or above the level of Assistant Professor (or equivalent).

Post-doctoral fellows are not eligible to be partnering PIs.

·     Preproposal is required; application submission is by invitation only.

·     Supports new or existing partnerships between two or three independent investigators focusing research across the whole research spectrum.

·     Investigators are expected to demonstrate within the application, the synergistic components (i.e., leveraging disciplines, expertise or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single investigator.

·     Emphasis on Synergy, Multi-disciplinary research, and Impact

·     Inclusion of an independent early career investigator is encouraged.

·     Inclusion of at least one military or U.S. Department of Veterans Affairs (VA) investigator is encouraged.

·     Preliminary data are required.

·     Clinical trials are not allowed.

·      The maximum allowable funding for the entire period of performance is $700,000 for direct costs

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

·      Maximum period of performance is 3 years

Translational Research Award – Preproposal is due July 26, 2019

Independent investigators at or above the level of Assistant Professor (or equivalent)

·     Preproposal is required; application submission is by invitation only.

·     Supports studies aiming to leverage existing biobanks, biorepositories, ongoing or completed clinical trials to address a translational question or problem in melanoma.

·     Emphasis on Translation and Impact.

·     Inclusion of DoD or VA participation is encouraged.

·     Preliminary data is required.

·     Clinical trials are not allowed.

·     The maximum allowable funding for the entire period of performance is $600,000 for direct costs

·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

·     Maximum period of performance is 3 years

A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $15 million (M) to the Department of Defense Peer Reviewed Alzheimer’s Research Program (PRARP) to support research which addresses the long-term consequences of traumatic brain injury (TBI) as they pertain to Alzheimer’s disease (AD) and related dementias (ADRD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 PRARP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

FY19 PRARP Overarching Challenges and Focus Areas:

All applications for FY19 PRARP Program Announcements must address at least one of the following FY19 Overarching Challenges.  The FY19 Overarching Challenges will be award mechanism-specific. 

FY19 PRARP Overarching Challenges are listed below.

PRARP FY19 Overarching Challenges
Paucity of Research Resources:  The paucity of research resources and models to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities and translate these findings
Paucity of Clinical Studies:  The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities
Diagnostics and Prognostics:  The need for technologies, tests, surveys, questionnaires, devices, biomarkers, or analyses to detect TBI and sequelae to include AD/ADRD utilizing new and/or pre-existing datasets
Epidemiology:  The paucity of epidemiological research to examine the interrelationship between TBI, risk and resiliency factors, and subsequent AD/ADRD for the military, Veteran, and civilian communities
Quality of Life:  The need for technologies, assessments, interventions, or devices to benefit individuals living with the common symptoms of TBI and/or AD/ADRD
Family and Care Support:  The need for technologies, assessments, interventions, or devices that enhance the lives of those providing care and families of individuals living with the common symptoms of TBI and/or AD/ADRD

In addition to addressing one or more of the specified FY19 Overarching Challenges, applications should also address at least one of the following FY19 Focus Areas in support of the FY19 Overarching Challenges.  An application that proposes research outside of the FY19 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be award mechanism-specific.

The PRARP FY19 Focus Areas are listed below.

PRARP FY19 Focus Areas

Mechanisms of Pathogenesis:  Identification of contributing mechanisms to include circuit dysfunction associated with TBI and subsequent AD/ADRD

Biomarkers:  Development of methods to diagnose, prognose, or characterize neurological changes or risk/resiliency factors associated with TBI and subsequent AD/ADRD

Quality of Life:  Research intended to alleviate, stabilize, or characterize the symptoms, or deficits, common to TBI and AD/ADRD

Family and Caregiver Support: Research intended to reduce the burden of care on the caregivers or families of individuals living with the common symptoms or deficits of TBI and AD/ADRD

Epidemiology:  Utilize new and existing studies and datasets to examine the relationships between risk and resiliency factors for TBI and subsequent AD/ADRD

Novel Target Identification:  Basic research (non-human) directly leading to identification of new targets for the development of existing or new investigational medicines, drugs, or agents for TBI and subsequent AD/ADRD

Nonpharmacological Interventions and Devices:  Research into non-medication-based interventions and devices to improve quality of life or caregiving for those living with the common symptoms of TBI and AD/ADRD

Bioinformatics:  Tools, including machine learning, to access, annotate, curate, store, and visualize large existing or novel datasets, e.g., multimodal magnetic resonance imaging (MRI), other imaging techniques, surveys, questionnaires, and diagnostics for TBI and subsequent AD/ADRD

The following is a summary of the FY19 PRARP Program Announcements.  Three award mechanisms will be offered for FY19. 

https://cdmrp.army.mil/funding/prarp

Convergence Science Research Award – Letter of Intent due June 26, 2019

Level I:  The Principal Investigator (PI) must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).  

Level II: The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Intent:  Support innovative or novel efforts to generate research resources, tools, or research efforts for researchers and/or practitioners in health sciences.

Applications must address one or more of the following FY19 PRARP Overarching Challenges:

·       Paucity of Research Resources

·       Paucity of Clinical Studies

·       Diagnostics and Prognostics

·       Epidemiology

Applications should address at least one of the following FY19 PRARP Focus Areas:

·       Mechanisms of Pathogenesis

·       Biomarkers

·       Epidemiology

·       Novel Target Identification

·       Bioinformatics

Research considering pharmacologic interventions is specifically discouraged under this mechanism.

Preliminary data, while not required, are encouraged.

Level I:

·      Maximum funding of $225,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

·      Indirect costs may be proposed in accordance with the institution's rate agreement.

Level II:

·      Maximum funding of $500,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

·      Indirect costs may be proposed in accordance with the institution's rate agreement.

Innovation in Care and Support award – Letter of Intent due June 26, 2019

Level 1: The PI must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).

Level II: The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent)

Intent: To support innovative research that improves the quality of life and care for individuals living with the common symptoms of TBI and/or Ad/ADRD and/or their families and care providers.

Applications must address one or more of the following FY19 PRARP Overarching Challenges:

·       Paucity of Clinical Studies

·       Diagnostics and Prognostics

·       Epidemiology

·       Quality of Life

·       Family and Care Support

Applications should address at least one of the following FY19 PRARP Focus Areas:

·       Biomarkers

·       Quality of Life

·       Family and Caregiver Support

·       Epidemiology

·       Nonpharmacological Interventions and Devices

·       Bioinformatics

·      Research considering pharmacologic interventions is specifically discouraged under this mechanism.

·      Preliminary data, while not required, are encouraged.

Level I:

·      Maximum funding of $225,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

·      Indirect costs may be proposed in accordance with the institution's rate agreement.

Level II:

·      Maximum funding of $500,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

·      Indirect costs may be proposed in accordance with the institution's rate agreement

Research Partnership Award – Letter of Intent due June 26, 2019

The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Intent: To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts.

Applications must include clearly stated plans for interactions between the partners.

Applications must address one or more of the following FY19 PRARP Overarching Challenges:

·       Paucity of Research Resources

·       Paucity of Clinical Studies

·       Diagnostics and Prognostics

·       Epidemiology

·       Quality of Life

·       Family and Care Support

Applications should address at least one of the following FY19 PRARP Focus Areas:

·       Mechanisms of Pathogenesis

·       Biomarkers

·       Quality of Life

·       Family and Caregiver Support

·       Epidemiology

·       Novel Target Identification

·       Nonpharmacological Interventions and Devices

·       Bioinformatics

·      Research considering pharmacologic interventions is specifically discouraged under this mechanism.

·      Preliminary data are required.

·      Funding limit is $1.3M in total costs. 

·      Maximum period of performance is 3 years.

·      Indirect costs may be proposed in accordance with the institution’s rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $22 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP)to support research addressing Gulf War Illness pathobiology, diagnosis, and treatment.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

https://cdmrp.army.mil/funding/gwirp

Idea Award – Preapplication is Due July 12, 2019

Independent investigators at all academic levels

·      Supports innovative high-risk/high-reward research in the earliest stages of development that will contribute to markers or treatments for Gulf War illness (GWI).

·      Impact and innovation are important review criteria.

·      Preliminary data not required.

·      Clinical trials not allowed.

·      Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program announcement/Funding Opportunity will qualify for a higher level of funding.  Application to this option is not a requirement for Idea Award submission.

·      Maximum funding of $150,000 for direct costs (plus indirect costs)

·      Maximum funding of $170,000 for direct costs with the Biorepository Contribution Option (plus indirect costs)

·      Maximum period of performance is 2 years

·      Preapplication is required; application submission is by invitation only.

Clinical Evaluation Award – Preapplication due July 12, 2019

Independent investigators at all academic levels

·      Supports translation of validated GWI research, including qualified and replicated preclinical findings, to a Gulf War Veteran population.

·      Statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints – or – proof-of-concept intervention trials (e.g., pilot, first in human, Phase I-IIa) are encouraged under this funding opportunity.

·      Preliminary data required.

·      Funding for this award mechanism must support research in a Gulf War Veteran population.  Proof of availability and access to necessary cohort(s) and/or critical reagents must be provided.

·      Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding. Applications to this option is not a requirement for Clinical Evaluation Award submission.

·      Clinical Consortium Collaboration Option: Applications including a commitment to work with the GWIRP-supported Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.  Clinical Consortium Collaboration options applications are not eligible to also submit under the Biorepository Contribution Option.  Application to this option not a requirement for Clinical Evaluation Award submission.

·     Maximum funding of $1,000,000 for direct costs (plus indirect costs)

·      Maximum funding of $1,020,000 for direct costs with the Biorepository Contribution Option (plus indirect costs).

·      Maximum funding of $1,200,000 for direct costs with the Clinical Consortium Collaboration Option (plus indirect costs).

·      Maximum period of performance is 3 years

·      Preapplication is required; application submission is by invitation only.

Therapeutic/Biomarker Trial Award - Preapplication due July 12, 2019

Independent investigators at all academic levels

·      Supports large-scale, pivotal (Phase IIb or III) trials that revolutionize the clinical management of GWI.

·        Objective biomarkers to measure the biological effect of an investigational therapeutic or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual with Gulf War Veteran or Gulf War Veteran subgroup must be included in the trial design.

·      Investigators must have experience in leading large-scale projects and demonstrated ability to implement a clinical project successfully.

·      Funding must be used to support a clinical trial.

·      Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding. Application to this option is not a requirement for Therapeutic/Biomarker Trial Award submission.

·       Clinical Consortium Collaboration Option: Applications including a commitment to work with the GWIRP-supported Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.  Clinical Consortium Collaboration Option applications are not eligible to also submit under the Biorepository Contribution Option.  Application to this option is not a requirement for Therapeutic/Biomarker Trial Award submission.

·      Funding must be used to support a clinical trial.

·     Maximum funding of $5,000,000 for direct costs (plus indirect costs)

·     Maximum funding of $5,020.000 for direct costs with the Biorepository Contribution Option (plus indirect costs)

·     Maximum funding of $5,500,000 for direct costs with the Clinical Consortium Collaboration Option (plus indirect costs)

·      Maximum period of performance is 4 years

·      Preapplication is required; application submission is by invitation only.

Patient-Provider and Health Communications Award - Preapplication due July 12, 2019

Independent investigators at or above the level of Assistant Professor

·      Supports projects aimed at tools and processes to raise awareness of GWI research and clinical findings within communities, including Veterans with GWI and/or their caregivers or advocates, healthcare providers who serve Veterans with GWI, or public health professional relevant to Veterans with GWI.

·      Maintenance and sustainment of the dissemination effort past the award period for continued awareness of GWI research and clinical findings is an important review criterion.

·      Must include a description of evaluation metrics and tracking to assist in measuring the success of the communication tool or process.

·      Must include at least one Gulf War Veteran with GWI, who will be integral throughout the planning and implementation of the research project.

·      Near-term impact is expected.

·      Clinical trials are not allowed.

·     Maximum funding of $700,000 for direct costs (plus indirect costs)

·     Maximum period of performance is 3 years

·      Preapplication is required; application submission is by invitation only.

New Investigator Award - Preapplication due July 12, 2019

PIs may apply under one of the following three eligibility categories:

Transitioning Postdoctoral Fellow: Senior postdoctoral fellows who have completed at least 3 years of postdoctoral training

Early-Career Investigator:Independent investigators within 5 years since their last training position

New GWI Researcher: Established independent investigators who have received less than $300,000 in Federally funded, non-mentored GWI research

·     Encourages applications from early-stage and established investigators new to the field of GWI research.

·     Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers is strongly encouraged.

·     Preliminary data are not required.

·      Clinical trials are not allowed.

·     Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding, Application to this option is not a requirement for New Investigator award submission.

·     Maximum funding of $500,000 for direct costs (plus indirect costs)

·     Maximum funding of $520,000 for direct costs with the Biorepository Contribution Option (plus indirect costs)

·     The maximum period of performance is 3 years

·      Preapplication is required; application submission is by invitation only.

Research Advancement Award - Preapplication due July 12, 2019

Independent investigators at all academic levels

• Supports preclinical research already supported by preliminary or published data in the GWI field that is ready for validation through expansion, replication, or comparative studies.
• Impact is an important review criterion.
• Preliminary data in the field of GWI and other supporting information is required.
• Clinical trials are not allowed.
• Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.  Application to this option is not a requirement for Research Advancement Award submission.
• Preapplication is required; application submission is by invitation only.
• Maximum funding of $700,000 for direct costs (plus indirect costs).
• Maximum funding of $720,000 for direct costs with the Biorepository Contribution Option (plus indirect costs).
• Maximum period of performance is 3 years.
• Preapplication is required; application submission is by invitation only.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense Hearing Restoration Research Program (HRRP)to support promising, necessary research for treatment of burdensome and very prevalent auditory system injury.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 HRRP Program Announcement and General Application Instruction for the following award mechanism are a posted on the Grants.gov website.

https://cdmrp.army.mil/funding/prgdefault

 

Focused Research Award – Preproposal due July 16, 2019

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

Preproposal is required; application submission is by invitation only.

·        Supports promising research that will accelerate drug discovery and therapeutic development for hearing restoration or accelerate advances in the assessment, diagnostics, and treatment of auditory dysfunction..

Must address one or more of the FY19 HRRP Focus Areas.

• Funding Level 1 supports exploratory, high-risk/high-reward research that is in the earliest stages of idea development.

• Funding Level 2 supports the advancement of more mature research toward clinical translation.

• Funding Level 2 may include a pilot clinical trial component where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.

• It is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the stage and maturity of the research, rather than the amount of the budget.

• Tinnitus or vestibular-related research is excluded.

Funding Level 1:

• Maximum funding of $250,000 for direct costs (plus indirect costs).

• Maximum period of performance is 2 years.

Funding Level 2:

• Maximum funding of $1,000,000 for direct costs (plus indirect costs).

• Maximum period of performance is 3 years.

Funding Level 2 with Pilot Clinical Trial Option:

• Maximum funding of $1,250,000 for direct costs (plus indirect costs).

• Maximum period of performance is 3 years.

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the HRRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $14 million (M) to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

Applications submitted to the FY19 LCRP must address at least one of the nine Areas of Emphasis listed below:

• Identify innovative strategies for the screening and early detection of lung cancer.
• Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
• Identify innovative strategies for prevention of the occurrence of lung cancer.
• Identify innovative strategies for the treatment of lung cancer.
• Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
• Develop or optimize predictive markers to assist with therapeutic decision-making.
• Understand mechanisms of resistance to treatment (primary and secondary).
• Understand contributors to lung cancer development other than tobacco.
• Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).

Military Relevance:  The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families.  Military relevance will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review.  Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:

• Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
• Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators
• Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area
• Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
• Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

https://cdmrp.army.mil/funding/lcrp

Concept Award – Letter of Intent due July 24, 2019

• All investigators at or above the level of postdoctoral fellow (or equivalent)
• Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.
• Emphasis on innovation.
• Research involving human subjects or specimens must be either exempt under Title 32, Code of Federal Regulations (CFR), Part 219, Section 1049d) (32 CFR 219.104 [d]) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110).
• Clinical trials not allowed.
• Preliminary data discouraged (not consistent with intent of award mechanism).
• Relevance to Military Health strongly encouraged.
• Maximum funding of $100,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 1 year.

Career Development Award – Letter of Intent due August 1, 2019

• Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment
• Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs
• Must not have received more than $300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one or more federally or privately funded, non-mentored, peer-reviewed grants
• Mentor:  At or above the level of Associate Professor (or equivalent
• Must have a proven publication and funding record in lung cancer research
• Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.
• Clinical trials not allowed.
• Preliminary data not required.
• Relevance to Military Health strongly encouraged.
• Maximum funding of $250,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Idea Development Award – Preproposal due May 15, 2019

• Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or
• New Investigators:  Investigators that meet the following criteria at the application submission deadline date:
• • Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award
  • Be within 10 years of first faculty appointment (or equivalent)
• Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
• Emphasis on innovation and impact.
• New Investigators: Supports applicants early in their faculty appointments or in the process of developing independent research careers.
• Clinical trials not allowed.
• Preliminary data required, but may be from outside of lung cancer.
• Relevance to Military Health strongly encouraged.
• Maximum funding of $350,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Investigator-Initiated Translational Research Award – Preproposal due May 15, 2019

• Independent investigators at or above the level of Assistant Professor (or equivalent)
• Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.
• Intended to fund a broad range of translational studies.
• Clinical trials not allowed.
• Preliminary data required.
• Relevance to Military Health strongly encouraged.
• Maximum funding of $400,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Translational Research Partnership Award – Preproposal due May 15, 2019

• Investigators at or above the level of Assistant Professor (or equivalent)
• Supports partnerships between clinicians and research scientists that accelerate ideas in lung cancer into clinical applications.
• One partner is strongly encouraged to be from a Defense military treatment facility or laboratory, or Veterans Affairs medical center.
• Non-Traditional Partnerships are encouraged.
• Small-scale clinical trials allowed.
• Preliminary data required.
• Relevance to Military Health strongly encouraged.
• Maximum combined funding of $900,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP)to support innovative, high-impact prostate cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease.  Applications submitted to the FY19 PCRP must address one or more of the program’s Overarching Challenges:

·         Improve the quality of life for survivors of prostate cancer

·         Develop treatments that improve outcomes for men with lethal prostate cancer

·         Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

·         Define the biology of lethal prostate cancer to reduce death

 

https://cdmrp.army.mil/funding/pcrp

 

Health Disparity Research Award– Letter of Intent due June 27, 2019

Established Investigators:  Independent investigators at all levels

or

New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

·      Have the freedom to pursue individual aims without formal mentorship

·      Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award

·      Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family leave)

·      Supports ideas that have the high potential to make a significant impact in reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 

·      Primary emphasis will be placed on the potential impact of the proposed work.

·      Preliminary data are encouraged, but not required.

·      Proposed projects may include basic, translational, population science, or clinical research, including clinical trials.

·      Must address at least one of the FY19 PCRP Overarching Challenges

·      New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.

·      Established Investigators:

·      Maximum funding of $750,000 for direct costs (plus indirect costs).

·      New Investigators:

·      Maximum funding of $600,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

 

Translational Science Award – Letter of Intent due June 27, 2019

·      Independent investigators at all levels

·      Supports translational studies that will advance promising ideas into clinical applications.

·      The potential impact of the research is expected to be significant and go beyond an incremental advance.

·      Preliminary data to support feasibility are required.

·      Proposed projects may include basic, translational, population science or clinical research, but must demonstrate clinical relevance. Clinical trials are not allowed.

·      Maximum funding of $750,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

 

Clinical Trial Award – Letter of Intent due June 27, 2019

·      Independent investigators at all levels

·      Supports hypothesis-based, early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II) to test interventions that will have a major impact on one or more of the FY19 PCRP Overarching Challenges.

·      Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other types.

·      Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place by the time of application submission.

·      Letter of support to demonstrate proof of possession of sufficient drug supply to conduct study must be provided (if appropriate).

·      Clinical trials are expected to be initiated within 12 months of the award date.

·      Maximum funding of $2,000,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 4 years.

 

Synergistic Population and Data Science Award – Letter of Intent is due June 27, 2019

·      Independent investigators with a faculty-level appointment (or equivalent)

·      Supports multi-institutional partnerships that will leverage existing prostate cancer patient databases and/or cohorts to address high-impact questions responsive to the FY19 PCRP Overarching Challenges.

·      Allows for development of infrastructure to facilitate access to multiple databases/cohorts, as well as conducting hypothesis-based studies utilizing the multi-institutional datasets.

·      Minimum of three institutions and three patient databases and/or cohorts is required.

·      Maximum funding of $1,500,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $5 million (M) to the Department of Defense Lupus Research Program (LRP)to support that support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 LRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY19 LRP must address at least one of the five Focus Areas listed below:

• Understand lupus disease heterogeneity in risk of disease, presentation, clinical course, and outcomes including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, health economics, socioeconomic studies, environmental studies, and epidemiological.
• Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus over time, strategies and technologies to subtype patients, and understanding lupus disease mechanisms. 
• Improve quality of life of life of patients with lupus.
• Understand how the underlying genetic components and gene environment interactions of lupus disease relate to clinical disease characteristics using functional genomic studies.
• Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genomics of lupus disease in particular tissues, and metabolomics and how understanding the underlying pathobiology will improve quality of life of patients.

 

https://cdmrp.army.mil/funding/lrp

 

 

Concept Award – preproposal due June 7, 2019

Investigators at all academic levels

·        Preproposal is required; application submission is by invitation only.

·        Supports highly innovative, untested, potentially groundbreaking concepts in lupus research

·        Emphasis is on innovation

·        Clinical trials are not allowed

·        Preliminary data is not required

·       The maximum allowable funding for the entire period of performance is of $200,000 for total costs.

·       The maximum period of performance is 2 year

 

Impact Award - preproposal due June 7, 2019

Investigators at or above Assistant Professor (or equivalent)

·        Preproposal is required; application submission is by invitation only.

·        Supports high-risk/high-reward research

·        Emphasis is on impact

·        Clinical trials are not allowed

·        Preliminary data is encouraged but not required

·       The maximum allowable funding for the entire period of performance is $525,000 in total costs

·       The maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $12 million (M) to the Department of Defense Reconstructive Transplant Research Program (RTRP) to support research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The RTRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 RTRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

Focus Areas:  To meet the intent of the FY19 RTRP Idea Discovery Award and Investigator-Initiated Research Award mechanisms, applicants must address at least one of the FY19 RTRP Focus Areas listed below:

• ·         Reduce the risks of VCA-associated immunosuppression
• o    Define the unique mechanisms of VCA immunogenicity
• o    Develop novel approaches for improving VCA immune tolerance
• o    Identify unique immunosuppression requirements for VCA compared to other solid organ transplants
• ·         Develop reliable non-invasive methods or tools for monitoring VCA graft rejection
• o    Develop reliable non-invasive biomarkers for monitoring chronic VCA graft rejection in a large animal model
• o    Identify and/or validate new peripheral biomarkers for acute and chronic rejection
• o    Develop assays or devices for clinical graft monitoring utilizing validated biomarkers
• ·         Advance existing or develop innovative ex vivo tissue preservation strategies to extend the timeline between procurement and transplantation
• o    Develop novel approaches and models for perfused, hypothermic, high subzero and low subzero, or static preservation strategies
• o    Determine the extent to which VCA tissue preservation technology impacts VCA immunogenicity

 

https://cdmrp.army.mil/pubs/press/2019/19rtrppreann

 

Idea Discovery Award

Investigators at or above the level of postdoctoral fellow (or equivalent)

·         Supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods.

·         Innovation is the most important review criterion.

·         Project should include a well-formulated testable hypothesis based on strong scientific rationale and study design.

·         Preliminary or published data that supports the rationale are strongly encouraged.

·         Preproposal is required; full application submission is by invitation only.

• ·         Applications must address at least one of the FY19 RTRP Focus Areas.

·       Maximum funding of $500,000 for total costs (direct plus indirect costs).

• ·       Maximum period of performance is 2 years.

 

Investigator-Initiated Research Award

Independent investigators at all academic levels (or equivalent)

·         Supports studies with the potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.

·         Preproposal is required; full application submission is by invitation only.

·         Preliminary or published data are required.

·         Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.

• ·         Applications must address at least one of the FY19 RTRP Focus Areas.

Individual PIs:

·       Maximum funding of $1 million (M) for total costs (direct plus indirect costs).

·       Maximum period of performance is 3 years.

Multiple PI Option:

·       Maximum funding of $1.5M for total costs (direct plus indirect costs).

Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural Funding Opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $3.2 million (M) to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support innovative, high-impact Duchenne muscular dystrophy research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The DMDRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 DMDRP Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on the Grants.gov website in June 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

IMPORTANT:  All applications for the FY19 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies.

Studies proposed under this award may include:

·         Delivery to skeletal muscle and heart (ligand assisted, nanoparticles, identification of biological barriers to delivery, alternative vectors)

·         Immunosuppression, and other strategies to deal with neutralizing antibodies

·         Re-dosing

·         Targeting muscle stem cells

·         Cell based therapies, including but not limited to: selection of novel cell types, expansion, root of delivery, differentiation, and integration

Studies proposed under this award should not include:

• ·         Therapies addressing secondary pathology of DMD (fibrosis, inflammation, muscle atrophy, oxidative stress, mitochondrial defects, abnormal peripheral circulation)
• ·         Small molecules
• ·         Efficacy testing absence of mechanistic understanding,
• ·         Evaluation of standard vectors or delivery technologies

 

https://cdmrp.army.mil/pubs/press/2019/19dmdrppreann

 

Idea Development Award

Independent investigators at all academic levels (or equivalent).

• ·         Supports the development of innovative, high-impact ideas that advance the understanding of DMD and ultimately lead to improved outcomes.
• ·         Preliminary data relevant to the proposed project are required.
• ·         Pre-application is required; application submission is by invitation only.
• ·         Clinical trials or applications including a clinical trial aim are not allowed
• ·         Individual PI:
• ·         Maximum funding of $350 thousand (K) in total costs
• ·         Maximum period of performance 2 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

Click the image to go to the conference information page.